{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:44:15Z","timestamp":1792601055145,"version":"4.5.0"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T00:00:00Z","timestamp":1791417600000},"content-version":"vor","delay-in-days":92,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-61582-8","type":"journal-article","created":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T15:33:58Z","timestamp":1783524838000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Pregnancy outcomes following maternal GLP-1 receptor agonist exposure: a systematic review and meta-analysis"],"prefix":"10.1038","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0009-3951","authenticated-orcid":false,"given":"Nusret","family":"Uysal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ersan","family":"Horoz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mesut","family":"Gungor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilgin","family":"Timarci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melih Kaan","family":"Sozmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baris","family":"Karadas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusuf Cem","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,8]]},"reference":[{"key":"61582_CR1","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ajog.2024.08.024","volume":"232","author":"RF Drummond","year":"2025","unstructured":"Drummond, R. F. et al. Glucagon-like peptide-1 receptor agonist use in pregnancy: A review. Am. J. Obstet. Gynecol. 232, 17\u201325 (2025).","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"8","key":"61582_CR2","doi-asserted-by":"publisher","first-page":"e242026","DOI":"10.1001\/jamahealthforum.2024.2026","volume":"5","author":"C Scannell","year":"2024","unstructured":"Scannell, C. et al. Prescription fills for semaglutide products by payment method. JAMA Health Forum 5(8), e242026 (2024).","journal-title":"JAMA Health Forum"},{"key":"61582_CR3","unstructured":"Centers for Disease Control and Prevention. Adult obesity facts [Internet]. Atlanta: CDC; 2024. Available at: https:\/\/www.cdc.gov\/obesity\/adult-obesity-facts\/index.html. Accessed Feb 21, 2026."},{"issue":"1","key":"61582_CR4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogc.2025.103191","volume":"48","author":"IO Lee","year":"2026","unstructured":"Lee, I. O. et al. Outcomes of maternal periconceptional exposure to glucagon-like peptide-1 receptor agonists: A scoping review of evidence and reporting trends. J. Obstet. Gynaecol. Can. 48(1), 103191 (2026).","journal-title":"J. Obstet. Gynaecol. Can."},{"issue":"2","key":"61582_CR5","doi-asserted-by":"publisher","first-page":"62","DOI":"10.4103\/0974-1208.69332","volume":"3","author":"S Pandey","year":"2010","unstructured":"Pandey, S. et al. The impact of female obesity on the outcome of fertility treatment. J. Hum. Reprod. Sci. 3(2), 62\u201367 (2010).","journal-title":"J. Hum. Reprod. Sci."},{"issue":"2","key":"61582_CR6","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1111\/cob.12048","volume":"4","author":"KA Sim","year":"2014","unstructured":"Sim, K. A. et al. Weight loss improves reproductive outcomes in obese women undergoing fertility treatment: A randomized controlled trial. Clin. Obes. 4(2), 61\u201368 (2014).","journal-title":"Clin. Obes."},{"issue":"4","key":"61582_CR7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/j.1728-4465.2010.00250.x","volume":"41","author":"S Singh","year":"2010","unstructured":"Singh, S. et al. Unintended pregnancy: Worldwide levels, trends, and outcomes. Stud. Fam. Plann. 41(4), 241\u2013250 (2010).","journal-title":"Stud. Fam. Plann."},{"issue":"4","key":"61582_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2023-083550","volume":"14","author":"K Dao","year":"2024","unstructured":"Dao, K. et al. Use of GLP-1 receptor agonists in early pregnancy and reproductive safety: A multicentre, observational, prospective cohort study based on the databases of six Teratology Information Services. BMJ Open 14(4), e083550 (2024).","journal-title":"BMJ Open"},{"issue":"2","key":"61582_CR9","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1001\/jamainternmed.2023.6663","volume":"184","author":"CE Cesta","year":"2024","unstructured":"Cesta, C. E. et al. Safety of GLP-1 receptor agonists and other second-line antidiabetics in early pregnancy. JAMA Intern. Med. 184(2), 144\u2013152. https:\/\/doi.org\/10.1001\/jamainternmed.2023.6663 (2024).","journal-title":"JAMA Intern. Med."},{"issue":"2","key":"61582_CR10","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1111\/dom.70334","volume":"28","author":"YC Chou","year":"2026","unstructured":"Chou, Y. C. et al. Unintentional periconceptional exposure to glucagon-like peptide-1 receptor agonists and adverse pregnancy outcomes: A nationwide cohort study in Taiwan. Diabetes Obes. Metab. 28(2), 1420\u20131430 (2026).","journal-title":"Diabetes Obes. Metab."},{"key":"61582_CR11","doi-asserted-by":"publisher","DOI":"10.1055\/a-2716-1639","author":"Z Lewin","year":"2025","unstructured":"Lewin, Z. et al. Glucagon-like peptide-1 receptor agonists among pregnancies with pregestational diabetes and its relationship with congenital malformations. Am. J. Perinatol. https:\/\/doi.org\/10.1055\/a-2716-1639 (2025).","journal-title":"Am. J. Perinatol."},{"issue":"4","key":"61582_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/bcpt.70021","volume":"136","author":"L Kolding","year":"2025","unstructured":"Kolding, L. et al. Pregnancy outcomes after semaglutide exposure. Basic Clin. Pharmacol. Toxicol. 136(4), e70021 (2025).","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"issue":"10","key":"61582_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.jogoh.2025.103046","volume":"54","author":"BBS Armstrong","year":"2025","unstructured":"Armstrong, B. B. S. et al. Evaluation of GLP-1 receptor agonists in obstetrics and perinatal outcomes: a systematic review and meta-analysis. J Gynecol Obstet Hum Reprod. 54(10), 103046 (2025).","journal-title":"J Gynecol Obstet Hum Reprod."},{"key":"61582_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","volume":"372","author":"MJ Page","year":"2021","unstructured":"Page, M. J. et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 372, n71 (2021).","journal-title":"BMJ"},{"issue":"6","key":"61582_CR15","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1080\/17446651.2020.1830759","volume":"15","author":"JP Fr\u00edas","year":"2020","unstructured":"Fr\u00edas, J. P. Tirzepatide: A glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes. Expert Rev. Endocrinol. Metab. 15(6), 379\u2013394 (2020).","journal-title":"Expert Rev. Endocrinol. Metab."},{"key":"61582_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1002\/bdra.20533","volume":"85","author":"JC Carey","year":"2009","unstructured":"Carey, J. C. et al. Determination of human teratogenicity by the astute clinician method: Review of illustrative agents and a proposal of guidelines. Birth Defects Res. A Clin. Mol. Teratol. 85, 63\u201368 (2009).","journal-title":"Birth Defects Res. A Clin. Mol. Teratol."},{"issue":"5","key":"61582_CR17","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2165\/00002018-200629050-00003","volume":"29","author":"L Hazell","year":"2006","unstructured":"Hazell, L. et al. Under-reporting of adverse drug reactions: a systematic review. Drug Saf. 29(5), 385\u2013396 (2006).","journal-title":"Drug Saf."},{"key":"61582_CR18","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1177\/009286150804200501","volume":"42","author":"M Lindquist","year":"2008","unstructured":"Lindquist, M. VigiBase, the WHO global ICSR database system: Basic facts. Drug Inf. J. 42, 409\u2013419 (2008).","journal-title":"Drug Inf. J."},{"key":"61582_CR19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne, J. A. et al. ROBINS-I: A tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355, i4919 (2016).","journal-title":"BMJ"},{"key":"61582_CR20","unstructured":"McMaster University, Evidence Prime. GRADEpro GDT: GRADEpro guideline development tool [Internet]. Available at: https:\/\/www.gradepro.org."},{"key":"61582_CR21","unstructured":"Wells GA, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses [Internet]. Available at: http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp."},{"key":"61582_CR22","unstructured":"European Commission Joint Research Centre. EUROCAT: guidelines for data registration [Internet]. Available at: https:\/\/eu-rd-platform.jrc.ec.europa.eu\/eurocat\/data-collection\/guidelines-for-data-registration_en. Accessed Feb 21, 2026."},{"issue":"7414","key":"61582_CR23","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"JP Higgins","year":"2003","unstructured":"Higgins, J. P. et al. Measuring inconsistency in meta-analyses. BMJ 327(7414), 557\u2013560 (2003).","journal-title":"BMJ"},{"issue":"7568","key":"61582_CR24","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1136\/bmj.333.7568.597","volume":"333","author":"J Lau","year":"2006","unstructured":"Lau, J. et al. The case of the misleading funnel plot. BMJ 333(7568), 597\u2013600 (2006).","journal-title":"BMJ"},{"issue":"8","key":"61582_CR25","doi-asserted-by":"publisher","first-page":"4102","DOI":"10.1111\/dom.16437","volume":"27","author":"CH Parker","year":"2025","unstructured":"Parker, C. H. et al. Glucagon-like peptide 1 (GLP-1) receptor agonists\u2019 use during pregnancy: Safety data from regulatory clinical trials. Diabetes Obes. Metab. 27(8), 4102\u20134108 (2025).","journal-title":"Diabetes Obes. Metab."},{"issue":"9","key":"61582_CR26","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70211","volume":"34","author":"A Broe","year":"2025","unstructured":"Broe, A. et al. Prescription drugs in pregnancy and congenital malformations: a population-based safety screening study. Pharmacoepidemiol Drug Saf. 34(9), e70211 (2025).","journal-title":"Pharmacoepidemiol Drug Saf."},{"issue":"3","key":"61582_CR27","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1097\/TEN.0b013e3181a5875e","volume":"19","author":"J Williams","year":"2009","unstructured":"Williams, J. et al. Case report: exenatide use during pregnancy. Endocrinologist 19(3), 119\u2013121 (2009).","journal-title":"Endocrinologist"},{"issue":"10","key":"61582_CR28","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.1111\/dme.12726","volume":"32","author":"D Greco","year":"2015","unstructured":"Greco, D. Normal pregnancy outcome after first-trimester exposure to liraglutide in a woman with Type 2 diabetes. Diabet Med. 32(10), e29\u2013e30 (2015).","journal-title":"Diabet Med."},{"issue":"3\u20134","key":"61582_CR29","first-page":"70","volume":"27","author":"M Ivani\u0161evi\u0107","year":"2018","unstructured":"Ivani\u0161evi\u0107, M. et al. Pregnancy outcome and liraglutide levels in serum and umbilical vein blood of a woman with type 2 diabetes. A case report. Gynaecol Perinatol. 27(3\u20134), 70\u201372 (2018).","journal-title":"A case report. Gynaecol Perinatol."},{"issue":"1","key":"61582_CR30","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1007\/s00592-022-01954-4","volume":"60","author":"S Burlina","year":"2023","unstructured":"Burlina, S. et al. A case report on use of dulaglutide during the first weeks of pregnancy in woman affected by type 2 diabetes mellitus. Acta Diabetol. 60(1), 137\u2013138 (2023).","journal-title":"Acta Diabetol."},{"key":"61582_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1002\/ijgo.15092","volume":"163","author":"K Skov","year":"2023","unstructured":"Skov, K. et al. Semaglutide and pregnancy. Int J Gynecol Obstet. 163, 700\u2013701 (2023).","journal-title":"Int J Gynecol Obstet."},{"issue":"9","key":"61582_CR32","volume":"15","author":"A Alghamdi","year":"2023","unstructured":"Alghamdi, A. et al. A case report of a pregnant woman with type 2 diabetes mellitus using dulaglutide during the first trimester of pregnancy. Cureus 15(9), e44644 (2023).","journal-title":"Cureus"},{"issue":"2","key":"61582_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.53388\/CRC2024013","volume":"7","author":"XM Zhu","year":"2024","unstructured":"Zhu, X. M. et al. Normal pregnancy outcome after first-trimester exposure to semaglutide in an overweight woman: a case report. Clin Res Commun. 7(2), 13 (2024).","journal-title":"Clin Res Commun."},{"issue":"10","key":"61582_CR34","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.2174\/0118715303252109231023115112","volume":"24","author":"\u015eE Do\u011fan","year":"2024","unstructured":"Do\u011fan, \u015eE. et al. Case series: Exposure to glucagon-like peptide-1 receptor agonist in the first trimester of pregnancy in two siblings. Endocr. Metab. Immune Disord. Drug Targets 24(10), 1237\u20131239 (2024).","journal-title":"Endocr. Metab. Immune Disord. Drug Targets"},{"issue":"11","key":"61582_CR35","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00592-024-02331-z","volume":"61","author":"M Molteni","year":"2024","unstructured":"Molteni, M. et al. Use of dulaglutide in a pregnant woman with type 2 diabetes until third trimester of pregnancy. Acta Diabetol. 61(11), 1491\u20131494 (2024).","journal-title":"Acta Diabetol."},{"key":"61582_CR36","volume":"109","author":"H \u00d6zdemir","year":"2025","unstructured":"\u00d6zdemir, H. et al. Safety of liraglutide during pregnancy: a case report. Neurotoxicol Teratol. 109, 107515 (2025).","journal-title":"Neurotoxicol Teratol."},{"key":"61582_CR37","doi-asserted-by":"publisher","DOI":"10.1007\/s00592-025-02601-4","author":"S Burlina","year":"2025","unstructured":"Burlina, S. et al. Dulaglutide plus dapaglifozin use until the second trimester of pregnancy in a woman with type 2 diabetes. Acta Diabetol. https:\/\/doi.org\/10.1007\/s00592-025-02601-4 (2025).","journal-title":"Acta Diabetol."},{"issue":"2","key":"61582_CR38","doi-asserted-by":"publisher","DOI":"10.1097\/og9.0000000000000077","volume":"2","author":"D Abushanab","year":"2025","unstructured":"Abushanab, D. et al. Exposure to High-Dose Liraglutide in a Pregnant Woman With Obesity. O G Open. 2(2), e077 (2025).","journal-title":"O G Open."},{"key":"61582_CR39","volume":"109","author":"B \u00d6zen","year":"2025","unstructured":"\u00d6zen, B. et al. Evaluation of exposures of glucagon-like peptide-1 receptor agonists during pregnancy: case series from a university\u2019s teratology information service. Neurotoxicol Teratol. 109, 107515 (2025).","journal-title":"Neurotoxicol Teratol."},{"key":"61582_CR40","doi-asserted-by":"publisher","DOI":"10.1177\/1753495X251346330","author":"A Morton","year":"2025","unstructured":"Morton, A. et al. Pregnancy outcomes following first trimester exposure to semaglutide. Obstet. Med. https:\/\/doi.org\/10.1177\/1753495X251346330 (2025).","journal-title":"Obstet. Med."},{"issue":"Suppl_3","key":"61582_CR41","first-page":"A4370717","volume":"152","author":"H Kumar","year":"2025","unstructured":"Kumar, H. Maternal GLP-1 receptor agonist exposure and the risk of congenital cardiovascular defects: A global pharmacovigilance study. Circulation 152(Suppl_3), A4370717 (2025).","journal-title":"Circulation"},{"key":"61582_CR42","unstructured":"Brown J. P. et al. GLP-1 receptor agonist continuation into the first trimester of pregnancy and risk of non-live birth and abnormal fetal growth: a target trial emulation. Pharmacoepidemiol Drug Saf. 34 (2025)."},{"issue":"Suppl1","key":"61582_CR43","doi-asserted-by":"publisher","first-page":"deae108041","DOI":"10.1093\/humrep\/deae108.041","volume":"39","author":"K Hviid","year":"2024","unstructured":"Hviid, K. et al. GLP-1 receptor agonist treatment in early pregnancy and risk of pregnancy complications - A nationwide cohort study. Hum. Reprod.. 39(Suppl1), deae108041 (2024).","journal-title":"Hum. Reprod.."},{"key":"61582_CR44","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.amjcard.2025.03.013","volume":"246","author":"M Hanif","year":"2025","unstructured":"Hanif, M. et al. Efficacy and safety of glucagon-like peptide-1 receptor agonist use during the first trimester in pregnant women with type 2 diabetes. Am. J. Cardiol. 246, 10\u201313 (2025).","journal-title":"Am. J. Cardiol."},{"issue":"Suppl_1","key":"61582_CR45","doi-asserted-by":"publisher","first-page":"deaf097.046","DOI":"10.1093\/humrep\/deaf097.046","volume":"40","author":"D Westergaard","year":"2025","unstructured":"Westergaard, D. et al. Obesity, implantation and early pregnancy - does GLP-1 play a role?. Hum. Reprod.. 40(Suppl_1), deaf097.046 (2025).","journal-title":"Hum. Reprod.."},{"key":"61582_CR46","unstructured":"Reproductive Toxicology Center. REPROTOX [Internet]. Available at: https:\/\/reprotox.org. Accessed Feb 21, 2026."},{"key":"61582_CR47","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1215356","volume":"14","author":"DRP Muller","year":"2023","unstructured":"Muller, D. R. P. et al. Effects of GLP-1 agonists and SGLT2 inhibitors during pregnancy and lactation on offspring outcomes: A systematic review of the evidence. Front Endocrinol (Lausanne) 14, 1215356 (2023).","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"61582_CR48","doi-asserted-by":"publisher","first-page":"e380","DOI":"10.1016\/S2214-109X(18)30029-9","volume":"6","author":"J Bearak","year":"2018","unstructured":"Bearak, J. et al. Global, regional, and subregional trends in unintended pregnancy and its outcomes from 1990 to 2014: estimates from a Bayesian hierarchical model. Lancet Glob Health. 6(4), e380\u2013e389 (2018).","journal-title":"Lancet Glob Health."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61582-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61582-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61582-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:39:36Z","timestamp":1791416376000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-61582-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,8]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["61582"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-61582-8","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,8]]},"assertion":[{"value":"12 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"31416"}}